PEPDar: A randomized prospective noninferiority study of ritonavir‐boosted darunavir for HIV post‐exposure prophylaxis

• Published in: HIV Medicine Vol. 17; no. 6; pp. 453 - 459
• Main Authors: Faetkenheuer, G., Jessen, H., Stoehr, A., Jung, N., Jessen, A. B., Kuemmerle, T., Berger, M., Bogner, J. R., Spinner, C. D., Stephan, C., Degen, O., Vogelmann, R., Spornraft-Ragaller, P., Schnaitmann, E., Jensen, B., Ulmer, A., Kittner, J. M., Haerter, G., Malfertheiner, P., Rockstroh, J., Knecht, G., Scholten, S., Harrer, T., Kern, W. V., Salzberger, B., Schuermann, D., Ranneberg, B.
• Format: Journal Article
• Language: English
• Published: England Wiley 01.06.2016
• Subjects: Adult; Anti-HIV Agents; Anti-HIV Agents - administration & dosage; Anti-HIV Agents - adverse effects; Darunavir; Darunavir - administration & dosage; Darunavir - adverse effects; ddc:no; Female; Germany; Human immunodeficiency virus; Humans; lopinavir; Male; occupational exposure; Post-Exposure Prophylaxis; Post-Exposure Prophylaxis - methods; Prospective Studies; Ritonavir; Ritonavir - administration & dosage; Ritonavir - adverse effects; sexual exposure; Treatment Outcome; Withholding Treatment; darunavir; lopinavir; sexual exposure; occupational exposure; post-exposure prophylaxis

Objectives PEPDar compared the tolerability and safety of ritonavir‐boosted darunavir (DRV/r)‐based post‐exposure prophylaxis (PEP) with the tolerability and safety of standard of care (SOC). The primary endpoint was the early discontinuation rate among the per‐protocol population. Methods PEPDar wa...